Cheryl Bushnell1, Janet Prvu Bettger1, Kevin M Cockroft1, Steven C Cramer1, Maria Orlando Edelen2, Daniel Hanley1, Irene L Katzan1, Soeren Mattke1, Dawn M Nilsen1, Tepring Piquado1, Elizabeth R Skidmore1, Kay Wing1, Gayane Yenokyan1. 1. From the Department of Neurology, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.B.); Duke University School of Nursing, Durham, NC (J.P.B.); Department of Neurosurgery, Radiology and Public Health Sciences, Pennsylvania State University, Hershey (K.M.C.); Department of Neurology (S.C.C.) and Anatomy and Neurobiology (S.C.C.), University of California, Irvine; RAND Health Advisory Services, RAND Corporation, Boston, MA (M.O.E., S.M.); Department of Neurology (D.H.) and Department of Biostatistics, Bloomberg School of Public Health (G.Y.), Johns Hopkins University Medical Center, Baltimore, MD; Center for Outcomes Research and Evaluation, Cleveland Clinic, Cleveland, OH (I.K.); Department of Rehabilitation and Regenerative Medicine (Occupational Therapy), Columbia University Medical Center, New York, NY (D.M.N.); RAND Health Advisory Services, RAND Corporation, Santa Monica, CA (T.P.); Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA (E.R.S.); and South West Advanced Neurological Rehabilitation, LLC, Phoenix, AZ (K.W.). 2. From the Department of Neurology, Wake Forest Baptist Medical Center, Winston-Salem, NC (C.B.); Duke University School of Nursing, Durham, NC (J.P.B.); Department of Neurosurgery, Radiology and Public Health Sciences, Pennsylvania State University, Hershey (K.M.C.); Department of Neurology (S.C.C.) and Anatomy and Neurobiology (S.C.C.), University of California, Irvine; RAND Health Advisory Services, RAND Corporation, Boston, MA (M.O.E., S.M.); Department of Neurology (D.H.) and Department of Biostatistics, Bloomberg School of Public Health (G.Y.), Johns Hopkins University Medical Center, Baltimore, MD; Center for Outcomes Research and Evaluation, Cleveland Clinic, Cleveland, OH (I.K.); Department of Rehabilitation and Regenerative Medicine (Occupational Therapy), Columbia University Medical Center, New York, NY (D.M.N.); RAND Health Advisory Services, RAND Corporation, Santa Monica, CA (T.P.); Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA (E.R.S.); and South West Advanced Neurological Rehabilitation, LLC, Phoenix, AZ (K.W.). maria_edelen@rand.org.
Abstract
BACKGROUND: About half of survivors with stroke experience severe and significant long-term disability. The purpose of this article is to review the state of the science and to make recommendations for measuring patient-centric outcomes in interventions for motor improvement in the chronic stroke phase. METHODS AND RESULTS: A 9-member expert panel reviewed evidence to identify measures of upper and lower extremity function used to date as outcomes in trials with patients who experienced a stroke ≥6 months before assessment. Outcome measures were screened using StrokEDGE consensus panel recommendations, and evaluated for availability of a published minimal clinically important difference. Measures meeting these criteria were further evaluated with regard to their level of measurement, psychometric properties, and ability of minimal clinically important difference to capture gains associated with improved function and clinical relevance to patients, to arrive at recommendations. A systematic literature review yielded 115 clinical trials of upper and lower extremity function in chronic stroke that used a total of 34 outcome measures. Seven of these had published minimal clinically important differences and were recommended or highly recommended by StrokEDGE. Those are the Fugl-Meyer Upper Extremity and Lower Extremity scales, Wolf Motor Function Test, Action Research Arm Test, Ten-Meter and Six-Minute Walk Tests, and the Stroke Impact Scale. All had evidence for their psychometric performance, although the strength of evidence for validity varied, especially in populations with chronic stroke Fugl-Meyer Upper and Lower Extremity scales showing the strongest evidence for validity. CONCLUSIONS: The panel recommends that the Fugl-Meyer Upper and Lower Extremity scales be used as primary outcomes in intervention trials targeting motor function in populations with chronic stroke. The other 6 measures are recommended as secondary outcomes.
BACKGROUND: About half of survivors with stroke experience severe and significant long-term disability. The purpose of this article is to review the state of the science and to make recommendations for measuring patient-centric outcomes in interventions for motor improvement in the chronic stroke phase. METHODS AND RESULTS: A 9-member expert panel reviewed evidence to identify measures of upper and lower extremity function used to date as outcomes in trials with patients who experienced a stroke ≥6 months before assessment. Outcome measures were screened using StrokEDGE consensus panel recommendations, and evaluated for availability of a published minimal clinically important difference. Measures meeting these criteria were further evaluated with regard to their level of measurement, psychometric properties, and ability of minimal clinically important difference to capture gains associated with improved function and clinical relevance to patients, to arrive at recommendations. A systematic literature review yielded 115 clinical trials of upper and lower extremity function in chronic stroke that used a total of 34 outcome measures. Seven of these had published minimal clinically important differences and were recommended or highly recommended by StrokEDGE. Those are the Fugl-Meyer Upper Extremity and Lower Extremity scales, Wolf Motor Function Test, Action Research Arm Test, Ten-Meter and Six-Minute Walk Tests, and the Stroke Impact Scale. All had evidence for their psychometric performance, although the strength of evidence for validity varied, especially in populations with chronic stroke Fugl-Meyer Upper and Lower Extremity scales showing the strongest evidence for validity. CONCLUSIONS: The panel recommends that the Fugl-Meyer Upper and Lower Extremity scales be used as primary outcomes in intervention trials targeting motor function in populations with chronic stroke. The other 6 measures are recommended as secondary outcomes.
Authors: J H Van der Lee; V De Groot; H Beckerman; R C Wagenaar; G J Lankhorst; L M Bouter Journal: Arch Phys Med Rehabil Date: 2001-01 Impact factor: 3.966
Authors: Jane E Sullivan; Beth E Crowner; Patricia M Kluding; Diane Nichols; Dorian K Rose; Rie Yoshida; Genevieve Pinto Zipp Journal: Phys Ther Date: 2013-05-23
Authors: Francesca Bosetti; James I Koenig; Cenk Ayata; Stephen A Back; Kyra Becker; Joseph P Broderick; S Thomas Carmichael; Sunghee Cho; Marilyn J Cipolla; Dale Corbett; Roderick A Corriveau; Steven C Cramer; Adam R Ferguson; Seth P Finklestein; Byron D Ford; Karen L Furie; Thomas M Hemmen; Costantino Iadecola; Lyn B Jakeman; Scott Janis; Edward C Jauch; Karen C Johnston; Patrick M Kochanek; Harold Kohn; Eng H Lo; Patrick D Lyden; Carina Mallard; Louise D McCullough; Linda M McGavern; James F Meschia; Claudia S Moy; Miguel A Perez-Pinzon; Ipolia Ramadan; Sean I Savitz; Lee H Schwamm; Gary K Steinberg; Mary P Stenzel-Poore; Michael Tymianski; Steven Warach; Lawrence R Wechsler; John H Zhang; Walter Koroshetz Journal: Stroke Date: 2017-07-27 Impact factor: 7.914
Authors: Khader A Almhdawi; Hanan B Jaber; Hanan W Khalil; Saddam F Kanaan; Awni A Shyyab; Zaid M Mansour; Alza H Alazrai Journal: Qual Life Res Date: 2021-01-02 Impact factor: 4.147
Authors: Corina Schuster-Amft; Jan Kool; J Carsten Möller; Raoul Schweinfurther; Markus J Ernst; Leah Reicherzer; Carina Ziller; Martin E Schwab; Simon Wieser; Markus Wirz Journal: Pilot Feasibility Stud Date: 2022-07-05
Authors: Long Chen; Bin Gu; Zhongpeng Wang; Lei Zhang; Minpeng Xu; Shuang Liu; Feng He; Dong Ming Journal: Front Med Date: 2021-06-22 Impact factor: 4.592
Authors: Helen Rodgers; Helen Bosomworth; Hermano I Krebs; Frederike van Wijck; Denise Howel; Nina Wilson; Tracy Finch; Natasha Alvarado; Laura Ternent; Cristina Fernandez-Garcia; Lydia Aird; Sreeman Andole; David L Cohen; Jesse Dawson; Gary A Ford; Richard Francis; Steven Hogg; Niall Hughes; Christopher I Price; Duncan L Turner; Luke Vale; Scott Wilkes; Lisa Shaw Journal: Health Technol Assess Date: 2020-10 Impact factor: 4.014
Authors: Jesse Dawson; Charles Y Liu; Gerard E Francisco; Steven C Cramer; Steven L Wolf; Anand Dixit; Jen Alexander; Rushna Ali; Benjamin L Brown; Wuwei Feng; Louis DeMark; Leigh R Hochberg; Steven A Kautz; Arshad Majid; Michael W O'Dell; David Pierce; Cecília N Prudente; Jessica Redgrave; Duncan L Turner; Navzer D Engineer; Teresa J Kimberley Journal: Lancet Date: 2021-04-24 Impact factor: 79.321
Authors: Sangeetha Madhavan; Anjali Sivaramakrishnan; Mark G Bowden; Neale R Chumbler; Edelle C Field-Fote; Trisha M Kesar Journal: Top Stroke Rehabil Date: 2021-02-18 Impact factor: 2.119
Authors: Maria-Arantzazu Ruescas-Nicolau; María Luz Sánchez-Sánchez; Sara Cortés-Amador; Sofía Pérez-Alenda; Anna Arnal-Gómez; Assumpta Climent-Toledo; Juan J Carrasco Journal: Int J Environ Res Public Health Date: 2021-04-29 Impact factor: 3.390